NEW YORK(GenomeWeb) – Proteomics firm Caprion said today that it has signed an agreement to license Integrated Diagnostics' Xpresys Lung cancer test.
The agreement gives Caprion exclusive rights to market and commercialize Xpresys Lung in Canada.
Xpresys is intended to aid doctors in identifying lung nodules detected via CT scans as likely benign. The test uses multiple-reaction monitoring mass spec to quantify the levels of 11 proteins in patient blood samples.
Caprion played a key role in development of Xpresys, collaborating with Indi on a significant portion of the biomarker discovery and validation work underlying the test. Indi launched the test in the US in 2013.
The license agreement is part of Caprion's larger strategy to use its mass spec expertise to position itself as a Canadian partner for firms looking to offer clinical diagnostics in the country.
"Xpresys Lung is an important addition to our clinical laboratory service business and enables us to provide new diagnostic tools for physicians inCanadawhich may aid them in reducing unnecessary invasive procedures for benign lung nodules – generating economic efficiencies for our healthcare system," Caprion CEO Martin LeBlanc said in a statement.
The company said it will first offer the test in Quebec and expand to other regions in Canada.
Under the agreement, Caprion will pay Indi royalties and several milestone payments. Further financial terms were not disclosed.